Last reviewed · How we verify
Treatment
At a glance
| Generic name | Treatment |
|---|---|
| Also known as | Group 1 ( treatment group), Treatment, Experimental group, placebo, ADXS11-001 |
| Sponsor | Novartis |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma (PHASE2)
- The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. (NA)
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- Phase I Trial of High-Density Theta Burst Stimulation (hdTBS) (PHASE1)
- Rosacea and Ivermectin (PHASE2)
- Attitude and Success Rate of Women With Pelvic Organ Prolapse on Self-management of Vaginal Pessary (NA)
- MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) (PHASE1)
- The Effect of Continuous Positive Airway Therapy on the Blood Pressure in Sleepy vs Non-sleepy Patients With Obstructive Sleep Apnea
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment CI brief — competitive landscape report
- Treatment updates RSS · CI watch RSS
- Novartis portfolio CI